• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Following FDA nod, Ferring plans launch for needle-free drug-delivery system

July 23, 2018 By Sarah Faulkner

Ferring PharmaceuticalsFerring Pharmaceuticals said last week that the FDA approved its injectable somatropin product for four additional pediatric indications: idiopathic short stature, short stature associated with Turner syndrome, short stature born small for gestational age with no catch-up growth by 2 – 4 years and growth failure in short stature homeobox-containing gene deficiency.

In connection with the new approvals, Ferring plans to launch a needle-free drug-delivery system for its somatropin product in September this year.

The drug, known as Zomacton, was previously cleared by the FDA to treat growth failure in children caused by an inadequate production of endogenous growth hormone, as well as the replacement of endogenous growth hormone in adults with a deficiency.

Ferring noted that roughly 3-5% of children in the U.S. have short stature and many of the available treatments require using needles.

“Parents struggle to deliver their child’s daily dose of growth hormone due to children’s fear and anxiety of needles,” Teresa Tucker, co-founder & patient advocate at The Magic Foundation, said in prepared remarks. “Parents and patients will welcome an option that is completely needle free.”

“We are expanding the Ferring endocrinology portfolio with new indications and a delivery system to meet patient needs,” Paul Navarre, CEO of Ferring Holding, added. “Many patients object to needles, no matter how small. Ferring will now offer the only completely needle-free option for treating these diseases.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pediatrics, Pharmaceuticals, Regulatory/Compliance Tagged With: ferringpharmaceuticals

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS